Global Pharmacogenomics Technology Theranostics Companion Diagnostics Market

Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Research Report 2023, Forecast to 2028

Global Pharmacogenomics Technology Theranostics Companion Diagnostics Market

Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Research Report 2023, Forecast to 2028


Analysis of the Pharmacogenomics Technology/Theranostics/CDx Market reveals emerging trends, consumer adoption rates, and competitive strategies among leading manufacturers worldwide.

Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!

Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period.

Data collected includes market dynamics, technology outlook, application development, and pricing trends. All of this is fed into a research model, which then produces relevant data for market research. Global market trend analysis is given including historical data, estimates to 2023 and compound annual growth rate (CAGR) forecast to 2028.

Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation.

2023 will be a tough year for much of the global economy, as the ongoing war in Ukraine continues to strain trade, especially in Europe, and the global economy remains reeling from the fallout from the COVID-19 pandemic.

But as China moves ever closer to fully reemerging from three years of government-imposed Covid isolation and reintegrating with the world, economic expectations are high.And with the global economy now facing significant challenges, including energy shortages, slowing growth and high inflation, China’s reopening could provide a much-needed and timely boost.

The report researches and analyzes the influence of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) industry in the new era of global post-COIVD-19 economy in 2023, and provides in-depth analysis and professional suggestions on the current development.

Market Segment by Product Type

PCR

In-situ Hybridization

Immunohistochemistry

Sequencing

Others

Market Segment by Product Application

Oncology

Neurological Disorders

Cardiovascular Disease

Immunological Disorders

Others

Finally, the report provides detailed profile and data information analysis of leading company.

Qiagen NV

GE Healthcare

Agilent Technologies

F Hoffman La Roche

Foundation Medicine

Thermo Fisher Scientific Inc.

Leica Biosystems Nussloch GmBH

Pfizer

Insights and Tools:

We follow a comprehensive process to estimate market size. Key industry dynamics, regulatory scenarios, and segmental dynamics are analyzed to understand their impact on demand over the forecast period. Macroeconomic indicators such as prices, income and demographic changes, demand changes, etc. are considered in estimating market size. We also provide an in-depth profile of the key players and discuss their market shares in the global market to derive the market value. In addition, we have an internal database that is regularly updated with key insights and press releases from key stakeholders in the relevant market.

The data is generally gathered in various arrangements such as charts, graphs, infographics, trends, documents and records from various manufacturers and retailers. Our analyst gather, collect, and interpret such data to form significant databases. Our team then works with large data volumes to analyze core developments, evaluate market estimations, and identify trends.

The market research includes historical and forecast data from like demand, application details, price trends, and company shares by geography, especially focuses on the key regions like United States, European Union, China, and other regions.

Research Objectives

1.To study and analyze the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) consumption (value) by key regions/countries, product type and application, history data from 2018 to 2022, and forecast to 2028.

2.To understand the structure of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market by identifying its various subsegments.

3.Focuses on the key global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) manufacturers, to define, describe and analyze the value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.

4.To analyze the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) with respect to individual growth trends, future prospects, and their contribution to the total market.

5.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

6.To project the consumption of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) submarkets, with respect to key regions (along with their respective key countries).

7.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

8.To strategically profile the key players and comprehensively analyze their growth strategies.

Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Research Report 2023, Forecast to 2028

1 Market Study Overview

1.1 Study Objectives

1.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduce

1.3 Combined with the Analysis of Macroeconomic Indicators

1.4 Brief Description of Research methods

1.5 Market Breakdown and Data Triangulation

2 Global Trend Summary

2.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Segment by Type

2.1.1 PCR

2.1.2 In-situ Hybridization

2.1.3 Immunohistochemistry

2.1.4 Sequencing

2.1.5 Others

2.2 Market Analysis by Application

2.2.1 Oncology

2.2.2 Neurological Disorders

2.2.3 Cardiovascular Disease

2.2.4 Immunological Disorders

2.2.5 Others

2.3 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Comparison by Regions (2018-2028)

2.3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2018-2028)

2.3.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2018-2028)

2.3.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2018-2028)

2.3.4 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2018-2028)

2.3.5 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2018-2028)

2.3.6 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2018-2028)

2.4 Basic Product Information

2.4.1 Basic Product Information & Technology Development History

2.4.2 Product Manufacturing Process

2.4.3 Interview with Major Market Participants

2.4.4 High-end Market Analysis and Forecast

2.5 Coronavirus Disease 2020 (Covid-19): Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Industry Impact

2.5.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Impact Assessment - Covid-19

2.5.2 Market Trends and Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Potential Opportunities in the COVID-19 Landscape

2.5.3 Measures / Proposal against Covid-19

3 Competition by Manufacturer

3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales and Market Share by Manufacturer (2018-2023)

3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Market Share by Manufacturer (2018-2023)

3.3 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Industry Concentration Ratio (CR5 and HHI)

3.4 Top 5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Manufacturer Market Share

3.5 Top 10 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Manufacturer Market Share

3.6 Date of Key Manufacturers Enter into Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market

3.7 Key Manufacturers Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Manufacturers

3.8 Mergers & Acquisitions Planning

4 Analysis of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Industry Key Manufacturers

4.1 Qiagen NV

4.1.1 Compan Detail

4.1.2 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Introduction, Application and Specification

4.1.3 Qiagen NV 132 Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)

4.1.4 Main Business Overview

4.1.5 Qiagen NV News

4.2 GE Healthcare

4.2.1 Compan Detail

4.2.2 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Introduction, Application and Specification

4.2.3 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)

4.2.4 Main Business Overview

4.2.5 Qiagen NV News

4.3 Agilent Technologies

4.3.1 Compan Detail

4.3.2 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Introduction, Application and Specification

4.3.3 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)

4.3.4 Main Business Overview

4.3.5 Agilent Technologies News

4.4 F Hoffman La Roche

4.4.1 Compan Detail

4.4.2 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Introduction, Application and Specification

4.4.3 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)

4.4.4 Main Business Overview

4.4.5 F Hoffman La Roche News

4.5 Foundation Medicine

4.5.1 Compan Detail

4.5.2 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Introduction, Application and Specification

4.5.3 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)

4.5.4 Main Business Overview

4.5.5 Foundation Medicine News

4.6 Thermo Fisher Scientific Inc.

4.6.1 Compan Detail

4.6.2 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Introduction, Application and Specification

4.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)

4.6.4 Main Business Overview

4.6.5 Thermo Fisher Scientific Inc. News

4.7 Leica Biosystems Nussloch GmBH

4.7.1 Compan Detail

4.7.2 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Introduction, Application and Specification

4.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)

4.7.4 Main Business Overview

4.7.4 Main Business Overview

4.8 Pfizer

4.8.1 Compan Detail

4.8.2 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Introduction, Application and Specification

4.8.3 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)

4.8.4 Main Business Overview

4.8.5 Pfizer News

5 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Segment by Big Type

5.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Sales and Market Share by Big Type (2018-2023)

5.1.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales and Market Share by Big Type (2018-2023)

5.1.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Market Share by Big Type (2018-2023)

5.2 PCR Sales Growth Rate and Price

5.2.1 Global PCR Sales Growth Rate (2018-2023)

5.2.2 Global PCR Price (2018-2023)

5.3 In-situ Hybridization Sales Growth Rate and Price

5.3.1 Global In-situ Hybridization Sales Growth Rate (2018-2023)

5.3.2 Global In-situ Hybridization Price (2018-2023)

5.4 Immunohistochemistry Sales Growth Rate and Price

5.4.1 Global Immunohistochemistry Sales Growth Rate (2018-2023)

5.4.2 Global Immunohistochemistry Price (2018-2023)

5.5 Sequencing Sales Growth Rate and Price

5.5.1 Global Sequencing Sales Growth Rate (2018-2023)

5.5.2 Global Sequencing Price (2018-2023)

5.6 Others Sales Growth Rate and Price

5.6.1 Global Others Sales Growth Rate (2018-2023)

5.6.2 Global Others Price (2018-2023)

6 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Segment by Big Application

6.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales Market Share by Big Application (2018-2023)

6.2 Oncology Sales Growth Rate (2018-2023)

6.3 Neurological Disorders Sales Growth Rate (2018-2023)

6.4 Cardiovascular Disease Sales Growth Rate (2018-2023)

6.5 Immunological Disorders Sales Growth Rate (2018-2023)

6.6 Others Sales Growth Rate (2018-2023)

7 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecast

7.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Sales and Growth Rate (2023-2028)

7.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Regions (2023-2028)

7.2.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast (2023-2028)

7.2.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast (2023-2028)

7.2.3 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast (2023-2028)

7.2.4 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast (2023-2028)

7.2.5 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast (2023-2028)

7.2.6 Other Regions Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast (2023-2028)

7.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Type (2023-2028)

7.3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales Forecast by Type (2023-2028)

7.3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Forecast by Type (2023-2028)

7.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Application (2023-2028)

7.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales Forecast by Application (2023-2028)

7.4.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Forecast by Application (2023-2028)

8 Market Analysis

8.1.1 Market Overview

8.1.2 Market Opportunities

8.1.3 Market Risk

8.1.4 Market Driving Force

8.1.5 Porter's Five Forces Analysis

8.1.6 SWOT Analysis

9 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Related Market Analysis

9.1 Upstream Analysis

9.1.1 Macro Analysis of Upstream Markets

9.1.2 Key Players in Upstream Markets

9.1.3 Upstream Market Trend Analysis

9.1.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Manufacturing Cost Analysis

9.2 Downstream Market Analysis

9.2.1 Macro Analysis of Down Markets

9.2.2 Key Players in Down Markets

9.2.3 Downstream Market Trend Analysis

9.2.4 Sales Channel, Distributors, Traders and Dealers

10 Research Findings and Conclusion

Tables & Figures:
Show more
Research Methodology:
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Pharmacogenomics Technology/Theranostics/CDx Market Size Estimation

To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.

Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.

Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.

We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.

Data Source

Secondary Sources

This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.

These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.

Market Size
  • Segmental value
  • Geographic Penetration
  • Product Adoption Rate for Different market
  • Journals, Websites, and Press Releases
  • Annual Reports and SEC Filings
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Market Intellix Data Repository
Market Position of Top Company
  • Product Financials
  • Geographic value Mix
  • Total Company value
  • Business/Segmental value Mix
Qualitative Analysis
  • Influence Factors
  • Market Potential
  • Market Risks and Opportunities
  • Industry Trends
  • Geographical Features
  • Government Policies
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Annual Reports
  • Industry Associations
  • Market Intellix Data Repository

Primary Sources

As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.

On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.

These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.

Key Data Information from Primary Sources

Primary Sources Parameters Key Data
Market Segments(by Application, by Type)
  • Value by Type
  • Status and Forecast
  • Value by Application
  • Value by Regions, Status and Forecast (2025-2031)
  • Value Market Share by Type
  • Value Growth Rate by Type
  • Value by Application
  • Percentage and Growth Rate by Application
  • Value Growth Rate and Market Share by Regions
  • Market Size Status and Forecast (2025-2031)
Total Market
  • Overall Size, Status and Forecast
  • Market Size Status and Forecast (2025-2031)
Frequently asked questions(FAQ's):
Why is the Pharmacogenomics Technology/Theranostics/CDx Market trending toward high growth trajectories?
A dynamic process in the Pharmacogenomics Technology/Theranostics/CDx Market is initiated by new entrants, including competitors from unrelated industries, in addition to the established players like Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., Illumina, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Danaher Corporation, Siemens Healthineers AG, Genomic Health, Inc., Foundation Medicine, Inc., Guardant Health, Inc., Invitae Corporation, Adaptive Biotechnologies Corporation, Natera, Inc., Personalis, Inc., ArcherDX, Inc., BGI Genomics Co., Ltd., 23andMe, Inc..
Is the Pharmacogenomics Technology/Theranostics/CDx Market shifting its focus from growth to value?
Recognize the areas along the Pharmacogenomics Technology/Theranostics/CDx Market's value chain where players are generating value. To get a complete picture, kindly read the entire report.
What are the major applications of the Pharmacogenomics Technology/Theranostics/CDx Market?
Depending upon the type of applications, the Pharmacogenomics Technology/Theranostics/CDx Market has been segmented into and other applications.
What is the current state of the Pharmacogenomics Technology/Theranostics/CDx Industry, and what is the projected growth trajectory through 2030?
In 2024, the Pharmacogenomics Technology/Theranostics/CDx Market share surpassed USD xx million, and between 2025 and 2030, it will grow at a CAGR of yy%.
What are the underlying opportunities in the Pharmacogenomics Technology/Theranostics/CDx Market?
The influx of capital into the Pharmacogenomics Technology/Theranostics/CDx Market, as well as the deployment of technologies designed to increase efficiency and yield high volume, are paving the way for promising market opportunities.
What is the estimated global market value of the Pharmacogenomics Technology/Theranostics/CDx Market?
The Pharmacogenomics Technology/Theranostics/CDx Market is expected to reach a considerable market valuation.